FDA Approved: QUILLIVANT XR — Supplemental Application (NextWave Pharmaceuticals, Inc)

View source ↗

Summary

FDA approved a supplemental application for QUILLIVANT XR, indicating a modification or addition to the existing NDA for this methylphenidate product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• QUILLIVANT XR (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

SUPPL AP for QUILLIVANT XR (METHYLPHENIDATE HYDROCHLORIDE)